Chart-Typ:
Zeitraum:
| Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables... ► Artikel lesen |
| Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update | PDUFA Target Date of December 13, 2025 for CARDAMYST (etripamil) Nasal Spray in Paroxysmal Supraventricular Tachycardia (PSVT) Promotional Launch Plans Set with Quick-Start Capability Upon Potential... ► Artikel lesen |
| Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update | FDA Accepted the Company's Response to the CRL for CARDAMYST (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST... ► Artikel lesen |
| Aquestive Therapeutics, Inc.: Aquestive Therapeutics Broadens Patent Estate for Anaphylm | New patents extend protection for Anaphylm into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe... ► Artikel lesen |
| Aquestive Therapeutics, Inc.: Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock | WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement... ► Artikel lesen |
| Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | FDA accepts NDA submission for Anaphylm; PDUFA date set for January 31, 2026Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDACompany accelerates Anaphylm global expansion... ► Artikel lesen |
| BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen |
| Astria Therapeutics, Inc.: Astria Therapeutics rekrutiert nun HAE-Patienten in der Europäischen Union für die Phase-3-Studie ALPHA-ORBIT | Astria Therapeutics, Inc. (Nasdaq:ATXS), ein Biopharma-Unternehmen mit Schwerpunkt auf der Entwicklung lebensverändernder Therapien für allergische und immunologische Erkrankungen, gab heute bekannt... ► Artikel lesen |
| Astria Therapeutics, Inc.: Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial | Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it has begun opening... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GROWN ROGUE INTERNATIONAL INC finden Sie auf Wallstreet Online.